SEC Filings

Filing date	Form	Description	View
08/24/21	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-008402.pdf 0001179110-21-008402.rtf 0001179110-21-008402.xls
08/24/21	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-008404.pdf 0001179110-21-008404.rtf 0001179110-21-008404.xls
08/24/21	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-21-008406.pdf 0001179110-21-008406.rtf 0001179110-21-008406.xls
08/23/21	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-108565.pdf 0001104659-21-108565.rtf 0001104659-21-108565.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
08/05/21	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001558370-21-010555.pdf 0001558370-21-010555.rtf 0001558370-21-010555.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
08/03/21	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-099441.pdf 0001104659-21-099441.rtf 0001104659-21-099441.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
06/28/21	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-085903.pdf 0001104659-21-085903.rtf 0001104659-21-085903.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
06/25/21	424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	View HTML 0001104659-21-085711.pdf 0001104659-21-085711.rtf 0001104659-21-085711.xls
06/24/21	424B5	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	View HTML 0001104659-21-085123.pdf 0001104659-21-085123.rtf 0001104659-21-085123.xls
06/21/21	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-21-082951.pdf 0001104659-21-082951.rtf 0001104659-21-082951.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Data provided by Kaleidoscope.

For SEC filings prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.